FDA Approves First Drug for Rare Skin Disorder, and It’s a Redosable Gene Therapy
Krystal Biotech’s Vyjuvek is approved to treat recessive and dominant forms of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The redosable gene therapy, applied to the skin, delivers a gene that gets cells to produce collagen that DEB patients lack.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed